Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development ...
TipRanks on MSN
Exicure announces near-term strategic priorities
Exicure’s (XCUR) ongoing Phase 2 study is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in ...
The clinical database has since been locked, and Exicure remains on track to report topline data in Q4 2025. Preparations are also underway for a potential Phase 3 trial. A full data publication from ...
Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism First-in-human findings with ...
Clinical data from independent investigator-initiated studies using [68Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary AldosteronismFirst-in-human findings with [¹77Lu]Lu-Pentix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback